Biopharmaceuticals

Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs that are produced using biotechnology. They are proteins (including antibodies), nucleic acids (DNA, RNA) used for therapeutic or in vivo diagnostic purposes, and are produced by means other than direct extraction from a native (non-engineered) biological source.

The first biopharmaceuticals were approved in the 1980s, and since then, they have become a central part of modern medicine. Biopharmaceuticals can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. They are isolated from natural sources—human, animal, or microorganism—by biotechnological methods and other highly specialized manufacturing processes.

History

The history of biopharmaceuticals began in the early 20th century with the development of vaccines and hormone therapies such as insulin, which was extracted from animal pancreases. With the advent of recombinant DNA technology in the 1970s, it became possible to produce proteins in living cells, marking the birth of modern biopharmaceuticals.

Production

The production of biopharmaceuticals is complex, involving recombinant DNA technology, cell culture, fermentation technology, and purification processes. Unlike traditional pharmaceuticals, which are synthesized through chemical processes, biopharmaceuticals are produced using living organisms. The most common organisms used in their production are bacteria, yeast, and mammalian cells.

Types of Biopharmaceuticals

Biopharmaceuticals can be classified into several categories, including:

• Monoclonal antibodies: Engineered proteins that specifically target certain cells, often used in cancer treatment.
• Vaccines: Biological preparations that provide active acquired immunity to a particular disease.
• Growth factors: Substances that stimulate cell growth and proliferation.
• Hormones: Chemical messengers that regulate various physiological processes.
• Enzymes: Proteins that catalyze biochemical reactions, used in the treatment of conditions such as lysosomal storage diseases.

Applications

Biopharmaceuticals have revolutionized the treatment of a wide range of diseases, including cancer, diabetes, autoimmune diseases, and infectious diseases. They offer targeted therapy with fewer side effects compared to traditional drugs.

Regulatory Considerations

The development and approval of biopharmaceuticals are governed by strict regulatory standards to ensure their safety, efficacy, and quality. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines for the development, production, and approval of biopharmaceuticals.

Challenges and Future Directions

Despite their success, the development and production of biopharmaceuticals face several challenges, including high manufacturing costs, complex production processes, and the need for specialized facilities. Additionally, as patents on biopharmaceuticals expire, the market is seeing an increase in biosimilars, which are similar but not identical to the original products, raising questions about efficacy and safety.

The future of biopharmaceuticals lies in the continued advancement of biotechnology and the development of new production methods that can reduce costs and improve accessibility. Personalized medicine, where treatments are tailored to the individual's genetic makeup, is also seen as a promising area for the application of biopharmaceuticals.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian